168 related articles for article (PubMed ID: 1909702)
1. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.
Koukkou E; Panayiotidis P; Alevizou-Terzaki V; Thalassinos N
J Clin Endocrinol Metab; 1991 Oct; 73(4):771-6. PubMed ID: 1909702
[TBL] [Abstract][Full Text] [Related]
2. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism.
Mariotti S; Caturegli P; Barbesino G; Del Prete GF; Chiovato L; Pinchera A
J Endocrinol Invest; 1991 Oct; 14(9):777-81. PubMed ID: 1761814
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokines in thyrotoxicosis.
Siddiqi A; Monson JP; Wood DF; Besser GM; Burrin JM
J Clin Endocrinol Metab; 1999 Feb; 84(2):435-9. PubMed ID: 10022397
[TBL] [Abstract][Full Text] [Related]
4. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism.
Wenisch C; Myskiw D; Gessl A; Graninger W
J Clin Endocrinol Metab; 1995 Jul; 80(7):2122-6. PubMed ID: 7541802
[TBL] [Abstract][Full Text] [Related]
5. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs.
Tsatsoulis A; Vlachoyiannopoulos PG; Dalekos GN; Johnson EO; Moutsopoulos HM
Eur J Clin Invest; 1995 Sep; 25(9):654-8. PubMed ID: 7498238
[TBL] [Abstract][Full Text] [Related]
6. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.
Mariotti S; Caturegli P; Barbesino G; Marinò M; Del Prete GF; Chiovato L; Tonacchera M; De Carli M; Pinchera A
Clin Endocrinol (Oxf); 1992 Nov; 37(5):415-22. PubMed ID: 1486691
[TBL] [Abstract][Full Text] [Related]
7. Decreased serum level of IL-7 in patients with active Graves' disease.
Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
[TBL] [Abstract][Full Text] [Related]
8. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
9. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
Bayer MF; Kriss JP; McDougall IR
J Nucl Med; 1985 Nov; 26(11):1248-56. PubMed ID: 3840528
[TBL] [Abstract][Full Text] [Related]
11. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
[TBL] [Abstract][Full Text] [Related]
12. Severe but not mild alterations of thyroid function modulate the density of thyroid-stimulating hormone receptors in the rat thyroid gland.
Denereaz N; Lemarchand-Beraud T
Endocrinology; 1995 Apr; 136(4):1694-700. PubMed ID: 7895680
[TBL] [Abstract][Full Text] [Related]
13. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
[TBL] [Abstract][Full Text] [Related]
14. [The association of Graves' disease with serum soluble interleukin 2 receptor].
Ren YZ; Song ZG
Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):264-5, 317. PubMed ID: 8221241
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptors as an index of the biological activity of thyroid hormones in hyperthyroidism.
Koukkou E; Panayiotidis P; Thalassinos N
J Endocrinol Invest; 1995 Apr; 18(4):253-7. PubMed ID: 7560805
[TBL] [Abstract][Full Text] [Related]
16. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
Chen JJ; Ladenson PW
J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
[TBL] [Abstract][Full Text] [Related]
17. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
18. Bone remodelling markers and serum cytokines in patients with hyperthyroidism.
Akalin A; Colak O; Alatas O; Efe B
Clin Endocrinol (Oxf); 2002 Jul; 57(1):125-9. PubMed ID: 12100080
[TBL] [Abstract][Full Text] [Related]
19. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
20. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]